Joyzyme Group publishes 2025 annual report

• Joyzyme published its annual report for year ended Dec. 31, 2025, highlighting a strategic pivot toward women’s health as fertility-related demand softens amid falling birth rates.
• Business diversification accelerated with acquisition of Hunan Keyue Biotechnology, completed June 26, 2025, shifting group mix toward healthcare products, caregiver services, and customer experience.
• Core fertility diagnostics remained main operating focus, with portfolio expanded to 34 biological reagents, including new Class I device registrations tied to chemiluminescence-based fertility assessment in late 2025.
• Brand strategy centered on Nutronic, positioning early-life nutrition as response to “fertility anxiety” while targeting higher-quality outcomes rather than volume growth.
• Management outlook for 2026 prioritizes e-commerce and wholesale expansion to reduce geographic reliance, alongside continued product innovation in Canada and PRC.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Joyzyme Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260427-12126210), on April 27, 2026, and is solely responsible for the information contained therein.